

Chad Landmon Discusses Teva's At-Risk Launch of Generic Pulmicort with The Pink Sheet

On November 24, 2008, The Pink Sheet reported on Teva's at-risk launch of a generic version of AstraZeneca's Pulmicort, which was halted by a temporary restraining order ("TRO") entered by the district court within a day after Teva launched its generic product. AVH's Chad Landmon discussed Teva's decision to launch and explained that the subsequent TRO "does place Teva at risk of losing the rest of its exclusivity period if it takes the court a long amount of time" to resolve the substantive issues. Landmon also explained that the district court was able to schedule a prompt preliminary injunction hearing less than a week after the TRO was entered because the parties had completed discovery and were just two months from going to trial.